OncoMatch/Clinical Trials/NCT06799065
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Is NCT06799065 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies ATX-295 for advanced solid tumors.
Treatment: ATX-295 — The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Breast Carcinoma
Ovarian Cancer
Triple-Negative Breast Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Cardiac function
Clinically significant (ie, active) or uncontrolled cardiovascular disease [excluded]
Clinically significant (ie, active) or uncontrolled cardiovascular disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Cancer Specialists · Sarasota, Florida
- SCRI Oncology Partners · Nashville, Tennessee
- MD Anderson Cancer Center · Houston, Texas
- NEXT Oncology · San Antonio, Texas
- NEXT Virginia · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06799065 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages